By SPC News Staff
The FDA expanded the indication for abatacept (Orencia, Bristol Myers Squibb) for the treatment of patients 24 months of age and older with active psoriatic arthritis (PsA).
Initially approved by the FDA in 2005, abatacept was used for treatment of moderate to severe rheumatoid arthritis (RA) before gaining approval for adults with active PsA in 2017. According to the company, the FDA’s approval for patients 24 months to 17 years old with PsA is based on evidence from